CWM LLC boosted its holdings in Edwards Lifesciences Corp (NYSE:EW) by 8.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,096 shares of the medical research company’s stock after purchasing an additional 82 shares during the quarter. CWM LLC’s holdings in Edwards Lifesciences were worth $210,000 as of its most recent SEC filing.
A number of other hedge funds have also bought and sold shares of EW. Executive Wealth Management LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $25,000. Sontag Advisory LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $26,000. Lindbrook Capital LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $27,000. Capital Financial Planning LLC purchased a new stake in Edwards Lifesciences in the fourth quarter worth $28,000. Finally, WP Advisors LLC purchased a new stake in Edwards Lifesciences in the first quarter worth $35,000. Institutional investors and hedge funds own 84.43% of the company’s stock.
A number of analysts have weighed in on EW shares. Raymond James reduced their target price on Edwards Lifesciences from $210.00 to $200.00 and set an “outperform” rating on the stock in a research note on Wednesday, April 24th. Barclays raised their price target on Edwards Lifesciences from $150.00 to $160.00 and gave the company an “underweight” rating in a research note on Monday, March 25th. Morgan Stanley raised their price target on Edwards Lifesciences from $180.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, March 18th. UBS Group raised their price target on Edwards Lifesciences from $175.00 to $180.00 and gave the company a “neutral” rating in a research note on Tuesday, March 12th. Finally, Canaccord Genuity restated a “buy” rating and set a $215.00 price target (up previously from $190.00) on shares of Edwards Lifesciences in a research note on Monday, March 18th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have issued a buy rating to the company. The stock has a consensus rating of “Hold” and an average price target of $187.00.
In related news, VP Catherine M. Szyman sold 1,474 shares of Edwards Lifesciences stock in a transaction that occurred on Thursday, February 21st. The stock was sold at an average price of $176.34, for a total transaction of $259,925.16. Following the completion of the transaction, the vice president now directly owns 15,905 shares in the company, valued at $2,804,687.70. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Mussallem sold 32,800 shares of Edwards Lifesciences stock in a transaction that occurred on Friday, March 8th. The shares were sold at an average price of $167.89, for a total value of $5,506,792.00. Following the transaction, the chief executive officer now owns 67,126 shares of the company’s stock, valued at $11,269,784.14. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 153,780 shares of company stock valued at $27,129,483. Company insiders own 1.63% of the company’s stock.
NYSE EW traded up $0.66 during trading on Wednesday, hitting $172.66. The company’s stock had a trading volume of 1,030,195 shares, compared to its average volume of 1,282,922. The company has a debt-to-equity ratio of 0.17, a quick ratio of 2.69 and a current ratio of 3.66. The company has a market cap of $35.84 billion, a PE ratio of 36.74, a P/E/G ratio of 2.22 and a beta of 0.85. Edwards Lifesciences Corp has a fifty-two week low of $134.38 and a fifty-two week high of $197.86.
Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Tuesday, April 23rd. The medical research company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.23 by $0.09. Edwards Lifesciences had a return on equity of 31.16% and a net margin of 20.03%. The firm had revenue of $993.00 million during the quarter, compared to analysts’ expectations of $989.87 million. During the same period last year, the business posted $1.22 earnings per share. The company’s revenue for the quarter was up 11.0% compared to the same quarter last year. On average, sell-side analysts predict that Edwards Lifesciences Corp will post 5.28 earnings per share for the current fiscal year.
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Featured Article: Municipal Bonds
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.